An Open Label, Phase Ia/Ib Dose Finding Study With BI 894999 Orally Administered Once a Day in Patients With Advanced Malignancies, With Repeated Administration in Patients With Clinical Benefit
Phase of Trial: Phase I
Latest Information Update: 03 Nov 2017
At a glance
- Drugs BI 894999 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Boehringer Ingelheim
- 31 Oct 2017 Planned End Date changed from 7 Feb 2019 to 15 Nov 2019.
- 31 Oct 2017 Planned primary completion date changed from 30 Oct 2017 to 15 Dec 2017.
- 22 Jun 2017 Planned End Date changed from 1 May 2018 to 7 Feb 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History